Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) [Trend Analysis] retains strong position in active trade, as shares scoring -0.79% to $0.69 in active trade session, while looking at the shares volume, around 1.44 Million shares have changed hands in this session. Anthera Pharmaceuticals, Inc. (ANTH) reported that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrants offered in the public offering.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Rodman &Renshaw, a unit of H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The Company intends to use the net proceeds from the public offering for clinical research and development purposes for SOLLPURA, including the RESULT, SIMPLICITY and EASY trials as well as enabling manufacturing and general corporate purposes. The firm has institutional ownership of 37.00%, while insider ownership included 0.10%. ANTH attains analyst recommendation of 2.60 with week’s performance of 13.51%. Investors looking further ahead will note that the Price to next year’s EPS is 6.20%.
Shares of QUALCOMM Incorporated (NASDAQ:QCOM) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -0.31% to close at $58.46. Bronstein, Gewirtz& Grossman, LLC reminds investors that a class action lawsuit has been filed against QUALCOMM Incorporated (QCOM) and certain of its officers, on behalf of shareholders who purchased Qualcomm securities between February 1, 2012, and January 17, 2017, both dates inclusive.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and failed to disclose that (1) Qualcomm was engaging and/or had been involved in anticompetitive conduct to preserve a monopoly for semiconductors used in mobile phones in violation of the FTC Act; (2) as a result, Qualcomm lacked effective internal controls over financial reporting; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times. Moving forward to saw long-term intention, the experts calculate Return on Investment of 11.90%. The stock is going forward its fifty-two week low with 21.90% and lagging behind from its 52-week high price with -16.97%. QCOM last month stock price volatility remained 1.34%.